Summary Background: Little is known about the preoperative predictive factors that could identify subsets of favorable patients who can be possibly cured with robot-assisted radical prostatectomy (RARP) alone in locally advanced prostate cancer (LAPCa). Our study was designed to identify clinical predictors of pathologic organ-confined disease (pOCD) in RARP setting. Methods: Between 2007 and 2013, clinicopathological and oncological data from 273 consecutive men undergoing robot-assisted RP with extended PLND for clinically LAPCa were reviewed in a single-institution, retrospectively. After exclusion of patients who received neoadjuvant hormone treatment before surgery, 186 subjects satisfied the final inclusion criteria. Results: Fourty-three patients (23.1% of total cohort) with preoperative clinically LAPCa patients were down-staged to pOCD following RARP. Preoperative prostate-specific antigen (PSA) level, preoperative PSAD, positive core percent, maximal tumor volume in any core, and biopsy Gleason score were significantly associated with down-staging into pOCD following RARP. Multivariate logistic regression analysis revealed that lower preoperative PSA (10 ng/mL) and maximal tumor volume in any core (70%) were independent predictors of pOCD following RARP.
level, preoperative PSAD, positive core percent, maximal tumor volume in any core, and biopsy Gleason score were significantly associated with down-staging into pOCD following RARP. Multivariate logistic regression analysis revealed that lower preoperative PSA (10 ng/mL) and maximal tumor volume in any core (70%) were independent predictors of pOCD following RARP.
Conclusions: Approximately 23% of preoperative clinically LAPCa patients were down-staged to pOCD following RARP. Preoperative PSA and maximal tumor volume in any biopsy core might be useful clinical predictors of pOCD in clinically LAPCa patients in RARP setting. ª 2017 Asian Surgical Association and Taiwan Robotic Surgical Association. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Despite the widespread application of prostate-specific antigen (PSA)-based screening leading to a profound stage migration in prostate cancer (PCa), as many as one-third of PCa cases have a high-risk feature that requires aggressive treatment. 1e3 Until recently, surgical treatment has not been commonly used to treat locally-advanced PCa (LAPCa). 4 Optimal disease management in these patients remains challenging, and strong advocates propose various treatment options, such as radical prostatectomy (RP), radiotherapy (RT), androgen deprivation therapy, and increasingly, a multimodal approach. 5 Surgery offers an attractive opportunity for tumor excision, either as definitive management or as a first step in multimodal therapy. 6 Surgery can also identify a substantial subset of men with favorable clinical features in whom additional therapy is not indicated. 1, 7 Approximately 20%e30% of men undergoing RP for clinical stage T3 PCa have pathological organconfined disease (pOCD). 8, 9 A study conducted at Memorial Sloan-Kettering Center followed 176 men with cT3 over a 20-year period. Within this cohort, only 64 patients received neoadjuvant hormone therapy (HT), and more than one-half (52%) of patients remained free of disease recurrence following RP at a mean follow-up time of 6.4 years. 8 During the last several years, an increased number of publications have discussed the use of minimally invasive techniques, particularly robot-assisted radical prostatectomy (RARP), in high-risk or locally-advanced PCa patients. Numerous studies noted that RARP demonstrated similar oncological outcomes to open surgery and other minimally invasive surgeries in this clinical scenario.
10e13 Although recent published data illustrate of the therapeutic potential and technical feasibility of RARP in LAPCa patients, little is known about preoperative predictive factors that can identify subsets of favorable patients who may benefit from RARP monotherapy without any further treatment.
This retrospective study was designed to evaluate these predictive factors with respect to down-staging to pOCD in clinically LAPCa cases following RARP.
Materials and methods

Study population and data collection
We retrospectively reviewed the data of 1138 PCa patients who underwent extraperitoneal RARP performed by a single surgeon at Severance Hospital between January 2007 and December 2013. Of these men, 273 consecutive LAPCa cases (stages cT3-4) with no lymph node or distant metastasis (cT3-4N0M0) were identified. After excluding 70 patients who received neoadjuvant treatment before surgery and 17 patients whose lymph node metastasis was not verified by pathology, 186 men undergoing robot-assisted RP with extended PLND satisfied the final inclusion criteria.
Preoperative characteristics, including age, body mass index, clinical stage, PSA, and prostate biopsy findings (Gleason grade, positive core percent, and maximal tumor volume in any biopsy core) were collected from electronic medical records. In most cases, TRUS-guided biopsy consisted of a minimum of 10 cores including a 2-core transition zone biopsy. Positive core percent were calculated using formulas: number of positive cores/total number of biopsy core. The clinical stages of all the prostate cancer patients included in this study were determined by 3.0T MRI system staging, and the upper normal limit for pelvic lymphadenopathy by prostate MRI was 5 mm.
The RARP and bilateral pelvic lymph node dissections (PLND) were carried out using our standardized extraperitoneal technique and protocol. 14 The indication for and use of a unilateral or bilateral nerve-sparing technique depended on individual patient characteristics. Clinical staging was assigned by the attending urologist according to the 2002 TNM system. Biopsy and pathological grading were performed according to the Gleason grading system, and Gleason scores were assigned by genitourinary pathologists.
Good clinical practice protocols
The study was carried out in agreement with the applicable laws and regulations, good clinical practices, and ethical principles as described in the Declaration of Helsinki. The institutional review board of the hospital approved the study protocol (Approval number: 4-2014-0619).
Statistical analysis
Continuous variable values are presented as the median and interquartile range (IQR). Differences in variables with a continuous distribution across dichotomous categories were assessed using the ManneWhitney U test. The Fisher exact or Chi-square tests were used to evaluate the association between categorical variables. We used univariate and multivariate logistic regression analysis to determine predictive variables of pOCD in 158 patients, excluding those lacking prostate biopsy parameters. Variables yielding P < 0.2 after univariate analysis were included in the multivariate analysis. Receivers operating characteristic (ROC) curves were constructed to obtain the cut-off values of PSA, Gleason biopsy grade, positive biopsy core percent, and maximal tumor volume in any biopsy core that would confer optimal sensitivity and specificity for predicting the pOCD of prostatectomy specimens. Statistical significance was indicated if P < 0.05, and all reported Pvalues are 2-sided. Statistical analyses were performed using SPSS 24.0 software (SPSS Inc., Chicago, IL, USA). 
Results
Prediction of pOCD in clinically LAPCa patients after RARP
After RARP, 43 patients (23.1% of total cohort) with preoperative clinically LAPCa patients were down-staged to pOCD following RARP. PSMs were found in 6 (14.0%) of pOCD and 58 (40.6%) of pathologically LAPCa (P Z 0.001). Preoperative serum PSA (P < 0.001), preoperative PSAD (P < 0.001), positive core percent (P Z 0.019), maximal tumor volume in any core (P Z 0.005), and biopsy Gleason score (P Z 0.002) were significantly associated with downstaging into pOCD after RARP ( Table 2 ). The area under the curve (AUC) for the discriminative ability of pOCD in clinically LAPCa patients was 0.680 for preoperative PSA and 0.617 and 0.641 for positive core percent and maximal tumor volume in any core, respectively (P < 0.05 for each variable). After grouping Gleason biopsy scores into five categories (6, 7 with primary Gleason pattern 3, 7 with primary Gleason pattern 4, 8, and 9), the AUC of biopsy Gleason score related to the discriminative ability of pOCD in clinically LAPCa was 0.647 (P Z 0.004). Table 3 shows results from univariate and multivariate logistic regression analyses used to predict pOCD in clinically LAPCa after RARP. The cut-off values conferring optimal sensitivity and specificity for the discriminative ability of pOCD in LAPCa patients using ROC curve were PSA at 10 ng/mL, positive core percent at 33.3%, maximal tumor volume in any core at 70%, and biopsy Gleason score at 7 with primary Gleason pattern 3. In univariate analyses, preoperative PSA level (10 ng/mL), positive core percent (33.3%), Maximal tumor volume in any core (70%), and biopsy Gleason score (7 with primary Gleason pattern 3) were associated with pOCD. Multivariate analysis revealed that lower preoperative PSA (10 ng/mL) and maximal tumor volume in any core (70%) were independent predictors of pOCD following RARP.
Discussion
The optimal treatment regimen for men with LAPCa is controversial. At this stage the tumors appears to extend beyond the prostatic capsule with invasion into the pericapsular tissue, apex, bladder neck, or seminal vesicle but is not associated with lymph node involvement or distant metastases. 15, 16 Until recently, surgical management was often disregarded in these individuals due to their increased risk of BCR, systemic progression, and worsening oncologic outcomes. 17e19 However, several recent studies related to high-risk PCa have presented alternative views. 7,20e22 In a Mayo Clinic study of men undergoing RP, cT3 was found in 841 (15%) of the 5662 patients. Of the cT3 patients, 661 (79%) men did not receive neoadjuvant HT. After a pathological review of these patients, 223 (27%) had pathologic stage T2 disease, again highlighting the high prevalence of clinical over-staging. 23 Moreover, Tai et al reported that even patients with pathological T3 or higher stages, there are still optimistically high chances of 3-year recurrence-free survival at 81.1% (pT3a), and 62.6% (pT3b-4), and concluded that radical prostatectomy is curative even for some locally advanced prostate cancers in a midterm follow-up. 24 In our cohort, approximately 22% of preoperative clinically LAPCa patients were down-staged to pOCD following RARP. However, according to the Surveillance, Epidemiology, and End Results data, only 6% of men with locally advanced, nonmetastatic disease are treated Table 2 Comparison of preoperative variables between pathologically organ-confined and non-organ confined groups after robot-assisted radical prostatectomy in patients with clinically locally-advanced prostate cancer.
Variables
Final pathology P 26 We evaluated preoperative predictive factors, such as PSA levels, positive core/total biopsy core percent, maximum cancer involvement in positive cores, and biopsy Gleason score, that can identify subsets of favorable pathologic outcomes in RARP setting. To the best of our knowledge, no previous RARP series has reported a preoperative predictive factors for predicting pathologic outcome after RARP in LAPCa. Our results indicated that lower preoperative PSA (10 ng/mL) and maximal tumor volume in any core (70%) were independent predictors of pOCD following RARP. When patients with LAPCa are well selected, RARP can offer an attractive opportunity for complete tumor excision without any further treatment.
This study has several potential limitations. First, its retrospective design may produce some sampling bias. Also, the study included data from patients treated at a single tertiary institution by one surgeon, the time frame of which encompassed the surgical learning curve and development of the robot technology. Another concern relates to missing biopsy variables from some patients, further decreasing the size of our cohort. Notwithstanding the limitations, this study identified relevant clinical evidence supporting the role of RARP in LAPCa patients for whom surgical intervention had been previously abandoned due to potentially over-staged based on clinical staging.
In conclusion, clinically LAPCa is still frequently overstaged based on pre-treatment clinical staging criteria. Preoperative variables, including PSA levels and maximum cancer involvement in positive cores might identify subsets of favorable patients who can be possibly cured with robotassisted radical prostatectomy (RARP) alone in clinically LAPCa.
